###begin article-title 0
FOXC2 controls formation and maturation of lymphatic collecting vessels through cooperation with NFATc1
###end article-title 0
###begin p 1
K.I. Ivanov and J. Cheng's present address is Division of Experimental Oncology, Multidisciplinary Oncology Center, University of Lausanne, 1066 Epalinges, Switzerland.
###end p 1
###begin p 2
V. Horsley's present address is Dept. of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, CT 06520.
###end p 2
###begin p 3
###xml 1038 1044 <span type="species:ncbi:9606">humans</span>
The mechanisms of blood vessel maturation into distinct parts of the blood vasculature such as arteries, veins, and capillaries have been the subject of intense investigation over recent years. In contrast, our knowledge of lymphatic vessel maturation is still fragmentary. In this study, we provide a molecular and morphological characterization of the major steps in the maturation of the primary lymphatic capillary plexus into collecting lymphatic vessels during development and show that forkhead transcription factor Foxc2 controls this process. We further identify transcription factor NFATc1 as a novel regulator of lymphatic development and describe a previously unsuspected link between NFATc1 and Foxc2 in the regulation of lymphatic maturation. We also provide a genome-wide map of FOXC2-binding sites in lymphatic endothelial cells, identify a novel consensus FOXC2 sequence, and show that NFATc1 physically interacts with FOXC2-binding enhancers. As damage to collecting vessels is a major cause of lymphatic dysfunction in humans, our results suggest that FOXC2 and NFATc1 are potential targets for therapeutic intervention.
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 338 355 338 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib40">Kukk et al., 1996</xref>
###xml 357 376 357 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib16">Dumont et al., 1998</xref>
###xml 378 400 378 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib84">Wigle and Oliver, 1999</xref>
###xml 402 425 402 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib35">Karkkainen et al., 2004</xref>
###xml 427 448 427 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">Francois et al., 2008</xref>
###xml 567 589 567 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib84">Wigle and Oliver, 1999</xref>
###xml 591 612 591 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">Francois et al., 2008</xref>
###xml 768 787 768 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib78">van der Putte, 1975</xref>
###xml 789 812 789 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib35">Karkkainen et al., 2004</xref>
The formation of lymphatic vessels, whose main function is to drain interstitial fluid from the tissues back to the blood circulation, begins only after the blood circulation is already functional. The initial steps of lymphatic development are controlled by the transcription factors Sox18 and Prox1 and VEGF-C and its receptor VEGFR-3 (Kukk et al., 1996; Dumont et al., 1998; Wigle and Oliver, 1999; Karkkainen et al., 2004; Francois et al., 2008). Expression of Prox1 is induced by Sox18 in a restricted subset of endothelial cells in the embryonic jugular veins (Wigle and Oliver, 1999; Francois et al., 2008). These VEGF-C-responsive cells sprout and migrate to form the primary lymphatic sacs, which further remodel to form a primary lymphatic capillary plexus (van der Putte, 1975; Karkkainen et al., 2004). The primary plexus undergoes further morphological and molecular changes to form a mature lymphatic network composed of lymphatic capillaries responsible for the uptake of lymph from the interstitial space and collecting lymphatic vessels that transport the lymph back to the blood circulation. Mature collecting vessels are characterized by a thin basement membrane, sparse pericyte coverage, and have intraluminal valves to prevent backflow of the fluid. Lymphatic capillaries, however, lack valves and a pericyte layer. These later steps of lymphatic vascular development, the maturation of the primary lymphatic plexus into functional collecting vessels and capillaries, are at present not well understood.
###end p 5
###begin p 6
###xml 38 43 38 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2</italic>
###xml 174 194 174 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib59">Petrova et al., 2004</xref>
###xml 317 322 317 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FOXC2</italic>
###xml 370 373 370 373 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 365 373 365 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2<sup>&#8722;/&#8722;</sup></italic>
###xml 429 449 429 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib59">Petrova et al., 2004</xref>
###xml 614 632 614 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">Brice et al., 2002</xref>
###xml 682 687 682 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FOXC2</italic>
###xml 815 834 815 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib52">Mellor et al., 2007</xref>
###xml 257 260 <span type="species:ncbi:9606">Man</span>
###xml 328 336 <span type="species:ncbi:9606">patients</span>
###xml 374 378 <span type="species:ncbi:10090">mice</span>
###xml 476 484 <span type="species:ncbi:9606">patients</span>
Loss of forkhead transcription factor Foxc2 leads to defects in lymphatic remodeling, failure to form lymphatic valves, and increased pericyte coverage of lymphatic vessels (Petrova et al., 2004). In lymphedema-distichiasis (Online Mendelian Inheritance in Man reference no. 153400), a disease caused by mutations in FOXC2, the patients have a similar phenotype to Foxc2-/- mice with abnormal lymphatic vessel pericyte coverage (Petrova et al., 2004). Lymphedema-distichiasis patients also show reflux of tracer in a lymphoscintigram, indicating failure or absence of valves in their collecting lymphatic vessels (Brice et al., 2002). Interestingly, a recent study shows linkage of FOXC2 mutations to varicose veins and primary valve failure in veins, suggesting that FOXC2 controls the formation of venous valves (Mellor et al., 2007).
###end p 6
###begin p 7
###xml 164 188 164 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">Crabtree and Olson, 2002</xref>
###xml 522 544 518 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib39">Kinoshita et al., 1997</xref>
###xml 546 565 542 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib55">Musaro et al., 1999</xref>
###xml 567 586 563 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib45">Macian et al., 2001</xref>
###xml 588 605 584 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib81">Wada et al., 2002</xref>
###xml 607 626 603 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib67">Sakuma et al., 2003</xref>
###xml 628 649 624 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib3">Bettelli et al., 2005</xref>
###xml 764 776 760 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib44">Macian, 2005</xref>
###xml 778 794 774 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib73">Takayanagi, 2007</xref>
###xml 796 816 792 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib27">Horsley et al., 2008</xref>
###xml 830 836 826 832 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NFATc1</italic>
###xml 940 964 936 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">de la Pompa et al., 1998</xref>
###xml 966 985 962 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib62">Ranger et al., 1998</xref>
###xml 847 851 <span type="species:ncbi:10090">mice</span>
The transcription factor NFATc1 belongs to a family of calcium-sensitive transcription factors activated by calcineurin-dependent dephosphorylation (for review see Crabtree and Olson, 2002). Activation of nuclear factor of activated T cells (NFAT) proteins results in exposure of a nuclear localization sequence and subsequent translocation to the nucleus. Once in the nucleus, NFATc1 interacts with other transcription factors, including AP-1, nuclear factor kappaB, Foxp3, and GATA, to form regulatory complexes on DNA (Kinoshita et al., 1997; Musaro et al., 1999; Macian et al., 2001; Wada et al., 2002; Sakuma et al., 2003; Bettelli et al., 2005). NFATc1 is implicated in the regulation of immune cells as well as in osteogenesis and hair follicle stem cells (Macian, 2005; Takayanagi, 2007; Horsley et al., 2008). Studies of NFATc1-deficient mice have also revealed an essential role for NFATc1 in the morphogenesis of cardiac valves (de la Pompa et al., 1998; Ranger et al., 1998).
###end p 7
###begin p 8
In this study, we have characterized the steps of lymphatic vascular maturation, which lead to the formation of two morphologically and molecularly distinct parts of the lymphatic vascular system: collecting lymphatic vessels and capillaries. We show that Foxc2 controls this process, and in the absence of Foxc2, lymphatic vessels fail to undergo transformation toward a lymphatic collecting vessel phenotype. Furthermore, we demonstrate that NFATc1 is a novel regulator of lymphatic vascular maturation and that it cooperates with Foxc2 in this process.
###end p 8
###begin title 9
Results
###end title 9
###begin title 10
Molecular characterization of developing collecting lymphatic vessels
###end title 10
###begin p 11
###xml 393 412 393 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib78">van der Putte, 1975</xref>
###xml 598 606 598 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 A</xref>
###xml 895 903 895 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 B</xref>
###xml 1172 1187 1172 1187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1, C and D</xref>
###xml 1270 1278 1270 1278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 E</xref>
###xml 205 210 <span type="species:ncbi:10090">mouse</span>
To characterize the process of collecting lymphatic vessel formation, we studied morphological changes and the expression of the lymphatic endothelial-specific markers VEGFR-3, Foxc2, Prox1, and LYVE-1 in mouse mesenteric lymphatic vessels during development. The mesenteric lymphatic primordia can first be identified at embryonic day (E) 13.5 near the splenic and superior mesenteric veins (van der Putte, 1975). At E14.5, staining for lymphatic endothelial receptor tyrosine kinase VEGFR-3 showed numerous isolated clusters or single lymphatic endothelial cells (LECs) extending long filopodia (Fig. 1 A and ). These cell clusters, located on both sides along the mesenteric blood vessels, migrate and sprout toward each other along and across the blood vessels. By E15.5, LECs form a mesh-like network of highly branched capillary-like vessels surrounding the mesenteric arteries and veins (Fig. 1 B). After E15.5, the mesenteric lymphatic capillary plexus undergoes substantial morphological changes, leading to formation of collecting lymphatic vessel trunks by E17.5, characterized by even diameter, presence of intraluminal valves, and absent or little branching (Fig. 1, C and D). These features become even more pronounced in the postnatal collecting vessels (Fig. 1 E).
###end p 11
###begin p 12
###xml 0 93 0 93 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Expression of lymphatic endothelial markers during formation of collecting lymphatic vessels.</bold>
Expression of lymphatic endothelial markers during formation of collecting lymphatic vessels. (A-T) Whole-mount immunofluorescent staining of wild-type mesenteric vessels at the indicated ages for VEGFR-3 (A-E), Foxc2 (F-J and P-T), and Prox1 (K-O and P-T). At E14.5, Foxc2 is expressed in a few LECs (arrow), whereas arterial SMCs are Foxc2 positive (arrowhead). (U) Schematic summary of the expression of lymphatic markers during lymphatic collecting vessel maturation. Bars, 100 microm.
###end p 12
###begin p 13
###xml 105 120 105 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1, A and K</xref>
###xml 511 519 511 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 F</xref>
###xml 583 591 583 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 G</xref>
###xml 1014 1039 1014 1039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1, G&#8211;J, L&#8211;O, and Q&#8211;T</xref>
###xml 1303 1318 1303 1318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1, D and E</xref>
###xml 1349 1369 1349 1369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib46">Makinen et al., 2005</xref>
On the molecular level, E14.5-15.5 lymphatic vessels express uniformly high levels of Prox1 and VEGFR-3 (Fig. 1, A and K). At E14.5, LYVE-1 expression was absent in lymphatic vessels in the skin, whereas the lymph sacs show high LYVE-1 expression (Fig. S1, B-E). Interestingly, in the mesenterium, only a small subset of LECs express LYVE-1 at this time point (Fig. S1, G and L). At E14.5, Foxc2 is mainly expressed in arterial smooth muscle cells (SMCs), and Foxc2 levels are high only in a few isolated LECs (Fig. 1 F). Strikingly, by E15.5, all LECs express high levels of Foxc2 (Fig. 1 G). Up-regulation of Foxc2 expression is followed by an increase in LYVE-1 levels, which becomes present in all LECs by E16.5 (Fig. S1, H-N). Between E15.5 and 16.5, the expression of first Foxc2 and then Prox1 begins to decrease except in the areas of characteristic constrictions, which delineate forming lymphatic valves, and by E17.5, only weak expression can be detected in the lymphangion segments between the valves (Fig. 1, G-J, L-O, and Q-T). Foxc2 and Prox1 down-regulation is followed by a decrease of VEGFR-3 and LYVE-1 at E17.5-postnatal day (P) 9, but VEGFR-3 remains high in the valve leaflets, whereas LYVE-1 expression becomes very low in all collecting LECs, as it has been reported previously (Fig. 1, D and E; and Fig. S1, J, K, O, and P; Makinen et al., 2005). In the fully mature postnatal collecting lymphatic vessels, the expression of Foxc2, Prox1, and VEGFR-3 in vessel trunks is even weaker, whereas the expression in the valves remains high.
###end p 13
###begin p 14
###xml 231 242 231 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2, A&#8211;J</xref>
###xml 420 439 416 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2, A&#8211;E and K&#8211;X</xref>
The presence of a thin basement membrane and a sparse coating with mural cells is another characteristic feature of collecting lymphatic vessels. We found that accumulation of basement membrane protein collagen IV starts at E16.5 (Fig. 2, A-J). NG2-positive mural cells start to appear around the forming collecting vessels at E17.5, whereas alpha smooth muscle actin (SMA)-positive SMCs are prominent only after birth (Fig. 2, A-E and K-X).
###end p 14
###begin p 15
###xml 0 104 0 104 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Formation of basement membrane and mural cell coating during maturation of lymphatic collecting vessels.</bold>
Formation of basement membrane and mural cell coating during maturation of lymphatic collecting vessels. (A-X) Whole-mount immunofluorescent staining of wild-type mesenteric vessels at the indicated ages for VEGFR-3 (A-E), collagen IV (F-J), SMA (K-O), and NG2 (P-X). Accumulation of basement membrane to collecting lymphatic vessels occurs at E16.5 (C and H, arrows), whereas recruitment of SMCs occurs between E17.5 and P9 (E and O, arrows), and NG2-positive mural cells appear around the vessels at E17.5 (R and V, arrows). Bars, 100 microm.
###end p 15
###begin p 16
###xml 129 137 129 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 U</xref>
In summary, the formation of lymphatic collecting vessels starts at E14.5-15.5, which is coincident with up-regulation of Foxc2 (Fig. 1 U). This is followed by remodeling of the primary capillary plexus and formation of a single lymphatic trunk, at which point the expression of Foxc2 decreases except in the areas of the forming lymphatic valves, and is further followed by a decrease in Prox1, VEGFR-3, and LYVE-1 expression. Accumulation of basement membrane proteins starts at E16.5 followed by recruitment of NG2-positive mural cells at E17.5 and SMCs postnatally. These data uncover a highly dynamic spatiotemporal expression profile for LEC markers during the formation and maturation of collecting lymphatic vessels and suggest that the change in Foxc2 expression is the critical first event of the maturation process.
###end p 16
###begin title 17
Loss of Foxc2 prevents formation of collecting lymphatic vessels
###end title 17
###begin p 18
###xml 200 203 200 203 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 195 203 195 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2<sup>&#8722;/&#8722;</sup></italic>
###xml 278 284 278 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3</xref>
###xml 495 510 495 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3, A and E</xref>
###xml 592 600 592 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 G</xref>
###xml 684 687 684 687 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 679 687 679 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2<sup>&#8722;/&#8722;</sup></italic>
###xml 726 741 726 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3, G and H</xref>
###xml 851 854 851 854 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 846 854 846 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2<sup>&#8722;/&#8722;</sup></italic>
###xml 931 936 931 936 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2</italic>
###xml 936 939 936 939 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 946 961 946 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3, I and J</xref>
###xml 1008 1011 1008 1011 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1003 1011 1003 1011 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2<sup>&#8722;/&#8722;</sup></italic>
###xml 1106 1124 1106 1124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">Burri et al., 2004</xref>
###xml 204 208 <span type="species:ncbi:10090">mice</span>
###xml 688 692 <span type="species:ncbi:10090">mice</span>
###xml 855 859 <span type="species:ncbi:10090">mice</span>
###xml 940 944 <span type="species:ncbi:10090">mice</span>
###xml 1012 1016 <span type="species:ncbi:10090">mice</span>
Up-regulation of Foxc2 at E15.5, which precedes the morphological and molecular changes in the maturing lymphatic network, suggested that Foxc2 controls lymphatic vascular maturation. Indeed, in Foxc2-/- mice, lymphatic vessels fail to down-regulate Prox1, VEGFR-3, and LYVE-1 (Fig. 3). In contrast, the collecting vessels in the mesentery of E17.5 heterozygous littermates show a normal expression pattern with low levels of VEGFR-3 and Prox1 in the lymphangion, high expression in the valves (Fig. 3, A and E), and uniformly low expression of LYVE-1 throughout the whole collecting vessel (Fig. 3 G). The lymphatic capillaries continue to express high levels of LYVE-1 both in Foxc2-/- mice and in heterozygous littermates (Fig. 3, G and H). The secondary lymphoid chemokine (SLC) is also highly expressed in the immature collecting vessels in Foxc2-/- mice, whereas it is present only in the valves of the collecting vessels of Foxc2+/+ mice (Fig. 3, I and J). In addition, the collecting vessels in Foxc2-/- mice are more highly branched, which may reflect incomplete intussusceptive vascular pruning (Burri et al., 2004).
###end p 18
###begin p 19
###xml 0 69 0 69 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2 is essential for the formation of collecting lymphatic vessels.</bold>
###xml 296 301 296 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2</italic>
###xml 301 304 301 304 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 391 394 391 394 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 386 394 386 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2<sup>&#8722;/&#8722;</sup></italic>
###xml 451 457 451 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Angpt2</italic>
###xml 498 501 498 501 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 493 501 493 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2<sup>&#8722;/&#8722;</sup></italic>
###xml 534 540 534 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Angpt2</italic>
###xml 395 399 <span type="species:ncbi:10090">mice</span>
###xml 502 506 <span type="species:ncbi:10090">mice</span>
Foxc2 is essential for the formation of collecting lymphatic vessels. (A-J) Mesenteric lymphatic vessels fail to down-regulate VEGFR-3, Prox1, and SLC in the absence of Foxc2. Whole-mount immunofluorescent staining for VEGFR-3 (A-D), Prox1 (E and F), LYVE-1 (G and H), and SLC (I and J) in E17.5 Foxc2-/- or control embryos. (C and D) Internalization of VEGFR-3 in lymphatic vessels of Foxc2-/- mice but not control E17.5 embryos. (K and L) Increased Angpt2 expression in lymphatic vessels of Foxc2-/- mice. In situ hybridization for Angpt2 (blue) and immunohistochemical staining for VEGFR-3 (red). Arrows, lymphatic valves (A, E, and I) or collecting lymphatic vessels (G and H); arrowheads, lymphatic capillaries; dashed lines, lymphatic vessels. Bars: (A, B, and E-J) 100 microm; (C, D, K, and L) 25 microm.
###end p 19
###begin p 20
###xml 178 198 178 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib48">Makinen et al., 2001</xref>
###xml 200 221 200 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib79">Veikkola et al., 2001</xref>
###xml 223 245 223 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib86">Wirzenius et al., 2007</xref>
###xml 394 402 394 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 C</xref>
###xml 434 437 434 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 429 437 429 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2<sup>&#8722;/&#8722;</sup></italic>
###xml 570 578 570 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 D</xref>
###xml 777 780 777 780 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 772 780 772 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2<sup>&#8722;/&#8722;</sup></italic>
###xml 864 870 864 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Angpt2</italic>
###xml 1062 1068 1062 1068 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Angpt2</italic>
###xml 1222 1239 1222 1239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">Gale et al., 2002</xref>
###xml 1241 1261 1241 1261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib71">Shimoda et al., 2007</xref>
###xml 1263 1285 1263 1285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib15">Dellinger et al., 2008</xref>
###xml 1324 1346 1324 1346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib15">Dellinger et al., 2008</xref>
###xml 1424 1445 1424 1445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib80">Veikkola et al., 2003</xref>
###xml 1534 1540 1534 1540 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Angpt2</italic>
###xml 1544 1549 1544 1549 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2</italic>
###xml 1582 1597 1582 1597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3, K and L</xref>
###xml 1720 1742 1720 1742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib65">Saaristo et al., 2002a</xref>
###xml 1744 1766 1744 1766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib86">Wirzenius et al., 2007</xref>
###xml 1881 1892 1881 1892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4, A&#8211;E</xref>
###xml 1913 1916 1913 1916 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1908 1916 1908 1916 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2<sup>&#8722;/&#8722;</sup></italic>
###xml 2096 2107 2096 2107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4, F&#8211;J</xref>
###xml 438 442 <span type="species:ncbi:10090">mice</span>
###xml 1079 1083 <span type="species:ncbi:10090">mice</span>
###xml 1875 1879 <span type="species:ncbi:10090">mice</span>
Activation of VEGFR-3 after binding to its ligand VEGF-C is followed by internalization of the receptor observed in cultured LECs and in sprouting lymphatic capillaries in vivo (Makinen et al., 2001; Veikkola et al., 2001; Wirzenius et al., 2007). We observed uniform membranous staining for VEGFR-3 in wild-type collecting vessels, which is consistent with a quiescent VEGF-C-VEGFR-3 pathway (Fig. 3 C). In contrast, VEGFR-3 in Foxc2-/- mice was concentrated in grainy dots and largely absent from the cell surface, which is similar to sprouting lymphatic capillaries (Fig. 3 D and Fig. S1 F). Although the exact reason for the increased VEGFR-3 internalization remains to be investigated, it is indicative of active VEGFR-3 signaling and further confirms the failure of Foxc2-/- lymphatic vessels to adopt a collecting vessel phenotype. Angiopoietin-2 (Ang2 and Angpt2), a ligand of Tie2 endothelial receptor tyrosine kinase, is important in the regulation of blood vascular maturation and stabilization but is also essential for normal lymphatic development. Angpt2-deficient mice display disorganized and hypoplastic lymphatic capillaries and an aberrant recruitment of periendothelial cells to lymphatic capillaries (Gale et al., 2002; Shimoda et al., 2007; Dellinger et al., 2008). Ang2 is produced by LECs in vivo (; Dellinger et al., 2008), and its expression is induced in cultured LECs upon treatment with VEGF-C (Veikkola et al., 2003). In agreement with the increased VEGFR-3 internalization, we observed higher levels of Angpt2 in Foxc2-deficient lymphatic endothelia (Fig. 3, K and L). Activation of VEGFR-3 also leads to enhanced sprouting of lymphatic capillaries, accompanied by formation of filopodia (Saaristo et al., 2002a; Wirzenius et al., 2007). We observed abundant lymphatic sprouting in the developing lymphatic vasculature in the skin of wild-type mice (Fig. 4, A-E). In contrast, Foxc2-/- lymphatic vessels contained numerous blunt-ended protrusions devoid of filopodia, which were closely associated with a surrounding layer of basement membrane protein collagen IV (Fig. 4, F-J).
###end p 20
###begin p 21
###xml 49 52 49 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 44 52 44 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2<sup>&#8722;/&#8722;</sup></italic>
###xml 0 58 0 58 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Defective sprouting of lymphatic vessels in <italic>Foxc2<sup>&#8722;/&#8722;</sup></italic> mice.</bold>
###xml 201 204 201 204 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 196 204 196 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2<sup>&#8722;/&#8722;</sup></italic>
###xml 284 287 284 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 279 287 279 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2<sup>&#8722;/&#8722;</sup></italic>
###xml 53 57 <span type="species:ncbi:10090">mice</span>
Defective sprouting of lymphatic vessels in Foxc2-/- mice. (A-J) Whole-mount immunofluorescent staining for VEGFR-3 (green), LYVE-1 (red), and collagen IV (white) of skin from E17.5 wild-type and Foxc2-/- embryos. Note the close association of collagen IV and aborted sprouts in Foxc2-/- lymphatic vessels (I and J), whereas no collagen is deposited around wild-type lymphatic vessels (D and E). Bars: (A and F) 100 microm; (B-E and G-J) 50 microm.
###end p 21
###begin p 22
###xml 41 46 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2</italic>
###xml 196 199 196 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 191 199 191 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2<sup>&#8722;/&#8722;</sup></italic>
Collectively, our data show that loss of Foxc2 leads to a failure in the maturation of the primary lymphatic plexus into functional collecting lymphatic vessels and capillaries. Instead, the Foxc2-/- lymphatic vasculature is characterized by a persistent expression of the lymphatic capillary markers Prox1, VEGFR-3, LYVE-1, and SLC, failure to down-regulate VEGFR-3 signaling, and abnormal capillary sprouting.
###end p 22
###begin title 23
NFATc1 is expressed in LECs and is controlled by PROX1 and VEGF-C
###end title 23
###begin p 24
###xml 72 75 72 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 67 75 67 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2<sup>&#8722;/&#8722;</sup></italic>
###xml 95 115 95 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib59">Petrova et al., 2004</xref>
###xml 281 309 281 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1">Armstrong and Bischoff, 2004</xref>
###xml 514 538 511 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">DasGupta and Fuchs, 1999</xref>
###xml 540 560 537 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib50">Maretto et al., 2003</xref>
###xml 647 652 644 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2</italic>
###xml 669 672 666 669 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 664 672 661 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2<sup>&#8722;/&#8722;</sup></italic>
###xml 689 692 686 689 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 684 692 681 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2<sup>&#8722;/&#8722;</sup></italic>
###xml 405 409 <span type="species:ncbi:10090">mice</span>
###xml 693 697 <span type="species:ncbi:10090">mice</span>
Failure to form intraluminal valves is a characteristic feature of Foxc2-/- lymphatic vessels (Petrova et al., 2004), which led us to investigate the potential for cooperation between Foxc2 and pathways implicated in the regulation of heart valve development such as Wnt and NFAT (Armstrong and Bischoff, 2004). We did not observe beta-galactosidase expression in the lymphatic valves of the Wnt reporter mice TOP-Gal or BAT-Gal, whereas strong LacZ staining was observed in cardiac valves as reported previously (DasGupta and Fuchs, 1999; Maretto et al., 2003; unpublished data). Similarly, reporter expression was not modified in the absence of Foxc2 in TOP-Gal;Foxc2-/- or BAT-Gal;Foxc2-/- mice (unpublished data).
###end p 24
###begin p 25
###xml 365 376 365 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5, A&#8211;H</xref>
###xml 671 695 671 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">de la Pompa et al., 1998</xref>
###xml 697 716 697 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib62">Ranger et al., 1998</xref>
###xml 718 736 718 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">Chang et al., 2004</xref>
###xml 801 807 801 807 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NFATc1</italic>
However, for NFATc1, we detected previously unsuspected expression and activity in the lymphatic vasculature. At E12.5, nuclear NFATc1 was present in LECs of the lymph sacs. At E13.5, NFATc1 was mainly detected in the cytoplasm and, at lower levels, in the nuclei of endothelial cells of the lymph sacs. Mostly nuclear localization was observed from E14.5 onwards (Fig. 5, A-H). Notably, no significant expression of NFATc1 was detected in blood vessels at E12.5-17.5 nor in other Prox1-expressing tissues, such as the spinal cord (Fig. S2, B and C; unpublished data), suggesting a LEC-specific function in addition to the previously described role in endocardial cells (de la Pompa et al., 1998; Ranger et al., 1998; Chang et al., 2004). The in situ hybridization analysis demonstrated expression of NFATc1 in lymphatic vessels, especially in the valves, further confirming our observations (Fig. S2, D-F). A more detailed analysis of Foxc2 and NFATc1 expression revealed that these transcription factors are present only in a subset of LECs and are largely coexpressed as determined by double staining (Fig. S2 G). Moreover, in embryonic and adult skin, Foxc2 expression is mainly detected in lymphatic collecting vessels, but not in capillaries, further confirming that Foxc2 is a regulator of collecting vessel identity (Fig. S2, H-J; unpublished data).
###end p 25
###begin p 26
###xml 0 44 0 44 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Expression and regulation of NFATc1 in LECs.</bold>
Expression and regulation of NFATc1 in LECs. (A-H) Immunofluorescent staining for NFATc1 (green), Prox1 (red), and DNA (blue) at E12.5-17.5. Arrowheads, cytoplasmic staining. (I) Western blotting for the indicated proteins of iLECs transfected with PROX1 siRNA, control siRNA, or iLECs and control cell line SW480A (a subclone of colon carcinoma cell line) transduced with AdPROX1 or control AdLacZ. (J and K) NFATc1 activation is VEGF-C and VEGFR-2 dependent. Cells were stimulated with the indicated growth factors or BSA in the presence and absence of CsA and stained for NFATc1 (red) and PROX1 (green). (J) Quantification of nuclear intensity of NFATc1 in iLECs. Data are presented as mean percentual nuclear intensity +/- SEM. **, P < 0.001. RU, relative intensity unit. Bars, 20 microm.
###end p 26
###begin p 27
###xml 203 223 203 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib60">Petrova et al., 2002</xref>
###xml 225 243 225 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib83">Wigle et al., 2002</xref>
###xml 476 484 476 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 I</xref>
###xml 572 580 572 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 I</xref>
###xml 321 326 <span type="species:ncbi:9606">human</span>
Because of the specific expression of NFATc1 in lymphatic but not blood vascular endothelial cells, we investigated the potential regulation of NFATc1 expression by PROX1, which controls LEC commitment (Petrova et al., 2002; Wigle et al., 2002). Indeed, overexpression of PROX1, using adenoviral gene transfer in primary human intestinal LECs (iLECs), increased NFATc1 levels, whereas PROX1 overexpression in nonendothelial cells did not have any effect on NFATc1 expression (Fig. 5 I). Consistently, siRNA-mediated knockdown of PROX1 resulted in decreased NFATc1 levels (Fig. 5 I).
###end p 27
###begin p 28
###xml 120 140 120 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib32">Johnson et al., 2003</xref>
###xml 332 352 332 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib74">Tammela et al., 2007</xref>
###xml 552 567 552 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5, J and K</xref>
###xml 634 652 634 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib57">Ogawa et al., 1998</xref>
###xml 654 672 654 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib53">Meyer et al., 1999</xref>
###xml 825 844 825 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib34">Joukov et al., 1998</xref>
###xml 964 979 964 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5, J and K</xref>
###xml 1084 1090 1084 1090 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NFATc1</italic>
###xml 79 84 <span type="species:ncbi:9606">human</span>
VEGF stimulates nuclear translocation of NFATc1 and increases proliferation in human pulmonary valve endothelial cells (Johnson et al., 2003). This led us to investigate whether VEGF-C, which has been shown to promote the formation of collecting vessels in addition to its role in lymphatic endothelial proliferation and sprouting (Tammela et al., 2007), can activate NFATc1 in LECs. Indeed, treatment of iLECs with VEGF-C resulted in strong accumulation of nuclear NFATc1, whereas control BSA-treated cells showed only little nuclear NFATc1 staining (Fig. 5, J and K). VEGF-E, a viral homologue of VEGF that signals through VEGFR-2 (Ogawa et al., 1998; Meyer et al., 1999), also increased nuclear NFATc1, whereas VEGF-C156S, a mutant form of VEGF-C that unlike wild-type VEGF-C does not bind to VEGFR-2 but only to VEGFR-3 (Joukov et al., 1998), did not have a marked effect on nuclear accumulation of NFATc1 in spite of the activation of ERK1/2 phosphorylation (Fig. 5, J and K; and ). In contrast to its effect on nuclear translocation of NFATc1, VEGF-C treatment did not increase NFATc1 mRNA levels (Fig. S3 B), and conversely, overexpression of PROX1 in LECs did not lead to a specifically nuclear increase in NFATc1 but rather to increased overall protein levels (Fig. S3 C). Collectively, our data indicate that NFATc1 is expressed in a subset of LECs and that its levels are controlled by PROX1, whereas its activity and nuclear translocation are regulated by VEGF-C through activation of VEGFR-2 or VEGFR-2-VEGFR-3 heterodimers.
###end p 28
###begin title 29
Inhibition of NFAT signaling prevents formation of collecting lymphatic vessels
###end title 29
###begin p 30
###xml 169 175 169 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Nfatc1</italic>
###xml 393 398 393 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2</italic>
###xml 398 401 398 401 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 408 423 408 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6, A and B</xref>
###xml 538 541 538 541 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 532 541 532 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Nfatc1<sup>&#8722;/&#8722;</sup></italic>
###xml 618 642 618 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">de la Pompa et al., 1998</xref>
###xml 644 663 644 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib62">Ranger et al., 1998</xref>
###xml 831 849 831 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib21">Graef et al., 2001</xref>
###xml 924 927 924 927 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 918 927 918 927 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Nfatc1<sup>&#8722;/&#8722;</sup></italic>
###xml 1034 1052 1034 1052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">Chang et al., 2004</xref>
###xml 1126 1131 1126 1131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2</italic>
###xml 1131 1134 1131 1134 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 1218 1236 1218 1236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">Chang et al., 2004</xref>
###xml 1385 1393 1385 1393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 C</xref>
###xml 1634 1645 1634 1645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6, D&#8211;K</xref>
###xml 151 155 <span type="species:ncbi:10090">mice</span>
###xml 267 271 <span type="species:ncbi:10090">mice</span>
###xml 402 406 <span type="species:ncbi:10090">mice</span>
###xml 542 546 <span type="species:ncbi:10090">mice</span>
###xml 677 681 <span type="species:ncbi:10090">mice</span>
###xml 928 932 <span type="species:ncbi:10090">mice</span>
###xml 1492 1496 <span type="species:ncbi:10090">mice</span>
Next, we studied whether inhibition of NFATc1 signaling affects lymphatic vascular development in vivo. The initial LEC commitment was not affected in mice deficient in Nfatc1, as determined by staining for Prox1 (unpublished data). However, lymphatic capillaries in mice surviving until E15.5 were abnormally patterned, tortuous, and widened, which is reminiscent of the lymphatic vessels in Foxc2-/- mice (Fig. 6, A and B). These data suggested that NFATc1 controls the remodeling steps of lymphatic vascular development. Because Nfatc1-/- mice die before the formation of fully mature collecting lymphatic vessels (de la Pompa et al., 1998; Ranger et al., 1998), we treated mice with cyclosporine A (CsA), an inhibitor of calcineurin activity, and thus dephosphorylation and nuclear translocation of NFAT transcription factors (Graef et al., 2001). CsA treatment at E11 reproduces the cardiac valve defects seen in Nfatc1-/- mice, whereas CsA administration at E12 does not affect the heart valves or the viability of the embryos (Chang et al., 2004). To avoid interference with heart development, we treated wild-type and Foxc2+/- pregnant females at E12.5-16.5 and analyzed the vasculature at E17.5. As expected (Chang et al., 2004), CsA reduced the nuclear localization of NFATc1 in LECs (Fig. S2, K-N), but it did not affect the viability and overall appearance of the embryos (Fig. 6 C). Similarly, the blood vasculature of CsA-treated embryos did not differ from that of the control mice and displayed normal formation of veins, arteries, and capillary bed, appropriate coverage with SMCs, and normal blood vascular density (Fig. 6, D-K; unpublished data).
###end p 30
###begin p 31
###xml 0 84 0 84 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Defective lymphatic and normal blood vessel development upon loss of NFAT signaling.</bold>
###xml 141 144 141 144 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 135 144 135 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NFATc1<sup>&#8722;/&#8722;</sup></italic>
###xml 553 556 549 552 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 548 556 544 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2<sup>+/&#8722;</sup></italic>
###xml 567 570 563 566 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 562 570 558 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2<sup>&#8722;/&#8722;</sup></italic>
Defective lymphatic and normal blood vessel development upon loss of NFAT signaling. (A and B) Abnormal lymphatic vessel patterning in NFATc1-/- embryos. Whole-mount immunofluorescent staining of E15.5 skin for LYVE-1. Bars, 200 microm. (C) Normal macroscopic appearance of E17.5 embryos after administration of CsA. (D-K) Normal blood vessel morphology and SMC coverage after administration of CsA. Whole-mount immunofluorescent staining for PECAM-1 (green) and SMA (red) of control and CsA-treated skin and mesenteric vessels of E17.5 wild-type, Foxc2+/-, and Foxc2-/- embryos. Mesent, mesentery. Bars: (skin) 200 microm; (mesentery) 100 microm.
###end p 31
###begin p 32
###xml 219 236 219 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7, A&#8211;P and Q</xref>
###xml 242 253 242 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig8">Fig. 8, A&#8211;H</xref>
###xml 334 340 334 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Nfatc1</italic>
###xml 340 343 340 343 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 390 393 390 393 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 385 393 385 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2<sup>&#8722;/&#8722;</sup></italic>
###xml 481 486 481 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2</italic>
###xml 486 489 486 489 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 499 510 499 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7, K&#8211;P</xref>
###xml 608 619 608 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7, A&#8211;P</xref>
###xml 669 674 669 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2</italic>
###xml 674 677 674 677 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 800 822 800 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7, F, N, P, and R</xref>
###xml 862 865 862 865 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 857 865 857 865 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2<sup>&#8722;/&#8722;</sup></italic>
###xml 927 938 927 938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig8">Fig. 8, I&#8211;L</xref>
###xml 951 957 951 957 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Angpt2</italic>
###xml 966 981 966 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig8">Fig. 8, M and N</xref>
###xml 1052 1055 1052 1055 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1047 1055 1047 1055 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2<sup>&#8722;/&#8722;</sup></italic>
###xml 1094 1099 1094 1099 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2</italic>
###xml 1099 1102 1099 1102 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 1109 1117 1109 1117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 O</xref>
###xml 1175 1180 1175 1180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2</italic>
###xml 1180 1183 1180 1183 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 1452 1467 1452 1467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7, S and T</xref>
###xml 1712 1715 1712 1715 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1707 1715 1707 1715 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2<sup>&#8722;/&#8722;</sup></italic>
###xml 344 348 <span type="species:ncbi:10090">mice</span>
###xml 394 398 <span type="species:ncbi:10090">mice</span>
###xml 563 567 <span type="species:ncbi:10090">mice</span>
###xml 678 682 <span type="species:ncbi:10090">mice</span>
###xml 749 753 <span type="species:ncbi:10090">mice</span>
###xml 866 870 <span type="species:ncbi:10090">mice</span>
###xml 1056 1060 <span type="species:ncbi:10090">mice</span>
###xml 1103 1107 <span type="species:ncbi:10090">mice</span>
###xml 1515 1519 <span type="species:ncbi:10090">mice</span>
###xml 1716 1720 <span type="species:ncbi:10090">mice</span>
In contrast, CsA treatment resulted in abnormal lymphatic vessel patterning, lymphatic vessel hyperplasia, defective remodeling of mesenteric collecting vessels, and recruitment of SMCs to dermal lymphatic capillaries (Fig. 7, A-P and Q; and Fig. 8, A-H), which are phenotypes consistent with the early remodeling defects observed in Nfatc1-/- mice and reminiscent of the phenotype of Foxc2-/- mice. These defects were especially pronounced in the lymphatic vessels of CsA-treated Foxc2+/- embryos (Fig. 7, K-P). Furthermore, the lymphatic vessels of CsA-treated mice failed to down-regulate VEGFR-3, Prox1 (Fig. 7, A-P), and LYVE-1 (unpublished data), and CsA-treated Foxc2+/- mice completely lacked lymphatic valves, whereas CsA-treated wild-type mice had a significantly reduced number of valves (Fig. 7, F, N, P, and R). Similar to lymphatic vessels in Foxc2-/- mice, we also observed increased internalization of VEGFR-3 (Fig. 8, I-L) and higher Angpt2 levels (Fig. 8, M and N). The blunt aborted sprouts seen in the lymphatic capillaries of Foxc2-/- mice were also present in CsA-treated Foxc2+/- mice (Fig. 7 O). Injection of FITC-dextran into the hind limbs of E17.5 Foxc2+/- CsA-treated embryos demonstrated abnormal outflow from the collecting lymphatic vessels to the precollector vessel branches, whereas only the collecting lymphatic vessel trunks were visualized in control embryos, further confirming loss of collecting vessel function (Fig. 7, S and T). Foxc2 was present in all LECs of CsA-treated mice, demonstrating that NFAT signaling does not control Foxc2 expression or protein stability (Fig. S2, O and P), thus, the lymphatic defects are not caused by the lack of Foxc2. Conversely, Foxc2-/- mice showed normal NFATc1 expression (unpublished data).
###end p 32
###begin p 33
###xml 0 78 0 78 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NFAT signaling is necessary for the formation of collecting lymphatic vessels.</bold>
###xml 437 438 437 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 496 497 496 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
NFAT signaling is necessary for the formation of collecting lymphatic vessels. (A-P) NFAT inhibition prevents maturation of lymphatic vessels. Whole-mount immunofluorescent staining for VEGFR-3 (green) and Prox1 (red) of mesenteries and skins of control (A-H) or CsA-treated (I-P) E17.5 embryos. Arrows, lymphatic valves. (Q) Quantification of mean lymphatic vessel width from control and CsA-treated E17.5 dermal lymphatic capillaries (n = 4). (R) Quantification of mesenteric lymphatic valves. n = 4 per genotype. *, P < 0.005; **, P < 0.001. (S and T) Lymph backflow in CsA-treated embryos. Collecting lymphatic vessels were visualized after high molecular weight FITC-dextran injection into E17.5 embryos. Data are presented as mean +/- SEM. Bars: (A-D and J-L) 100 microm; (E-H and M-P) 200 microm; (S and T) 500 microm.
###end p 33
###begin p 34
###xml 0 89 0 89 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Inhibition of NFAT signaling in vivo prevents maturation of collecting lymphatic vessels.</bold>
###xml 142 145 142 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 137 145 137 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2<sup>&#8722;/&#8722;</sup></italic>
###xml 391 394 391 394 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 386 394 386 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2<sup>+/&#8722;</sup></italic>
###xml 519 525 519 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Angpt2</italic>
###xml 587 593 587 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Angpt2</italic>
Inhibition of NFAT signaling in vivo prevents maturation of collecting lymphatic vessels. (A-H) Ectopic SMCs in lymphatic capillaries of Foxc2-/- and CsA-treated embryos. Whole-mount immunofluorescent staining for SMA (red) and Prox1 (green) of embryonic skin at E17.5. Arrows, SMA-positive lymphatic vessels. (I-L) Increased VEGFR-3 internalization in lymphatic vessels of CsA-treated Foxc2+/- embryos. Whole-mount immunofluorescent staining for VEGFR-3 (green/gray) and Prox1 (red). (M and N) Increased expression of Angpt2 upon inhibition of NFAT signaling. In situ hybridization for Angpt2 (blue) and immunohistochemical staining for VEGFR-3 (red) at E17.5. Boxed areas indicate regions shown at higher magnifications in J and L. Bars: (A-L)100 microm; (M and N) 25 microm.
###end p 34
###begin p 35
###xml 261 266 261 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2</italic>
###xml 309 314 309 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2</italic>
Collectively, these data show that suppression of NFATc1 activation during the late stages of embryogenesis prevents the formation and maturation of collecting lymphatic vessels without affecting blood vascular development in a manner highly reminiscent of the Foxc2 knockout phenotype. Moreover, loss of one Foxc2 allele strongly potentiates the effects of NFAT pathway inhibition. Together with the colocalization of Foxc2 and NFATc1 in developing collecting vessels, this suggests a functional cooperation between these two signaling cascades.
###end p 35
###begin title 36
ChIP-chip analysis of FOXC2-binding sites reveals cooperation with NFAT signaling
###end title 36
###begin p 37
###xml 975 994 975 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib56">O'Geen et al., 2006</xref>
###xml 1098 1104 1098 1104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig9">Fig. 9</xref>
###xml 1987 1995 1972 1980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig9">Fig. 9 B</xref>
###xml 77 81 <span type="species:ncbi:10090">mice</span>
###xml 86 90 <span type="species:ncbi:10090">mice</span>
###xml 593 598 <span type="species:ncbi:9606">human</span>
The similarities between the lymphatic maturation defects in Foxc2-deficient mice and mice with inhibited NFATc1 signaling led us to investigate a possible link between FOXC2 and NFATc1. FOXC2 and NFATc1 coimmunoprecipitated, indicating that the two transcription factors physically interact at least when overexpressed (Fig. S3 D). To gain a mechanistic understanding of the FOXC2-mediated transcriptional network, we performed genome-wide location analysis of endogenous FOXC2 in primary LECs. We used chromatin immunoprecipitation (ChIP) coupled with tiling microarrays covering the entire human genome (ChIP-chip) to produce an unbiased high resolution map of FOXC2-binding sites. For each ChIP-chip biological replicate, the immunoprecipitation was verified by Western blotting with anti-FOXC2 antibody (). ChIP DNA was amplified using the whole genome amplification method, which introduces very little bias compared with a commonly used linker-mediated PCR procedure (O'Geen et al., 2006). A total of 2350 FOXC2-binding sites were identified in LECs at a false discovery rate (FDR) of 0.1% (Fig. 9 and ). Because low yields of ChIP DNA from primary LECs precluded large-scale validation of ChIP-chip results by quantitative PCR, we used an alternative validation strategy by electrophoretic mobility shift assay (EMSA). We PCR amplified approximately200-bp fragments from nine randomly selected ChIP peak regions (Fig. S4 D) and tested them in EMSA with nuclear extracts from LECs transduced with FOXC2- (AdFOXC2) or control beta-galactosidase-expressing adenoviruses (AdLacZ). The selection of ChIP regions was unbiased with respect to model-based analysis of tiling array (MAT) score, p-value, FDR, or fold change. As expected, FOXC2 formed stable complexes with all ChIP region fragments but not with the control glyceraldehyde 3-phosphate dehydrogenase (GAPDH) fragment, and no specific complexes were observed with control nuclear extracts from cells transduced with AdLacZ (Fig. 9 B). The FOXC2-DNA complexes could be supershifted with anti-FOXC2 but not control antibodies (Fig. S4 B; unpublished data), and point mutations in the forkhead-binding motif totally abolished the probe interaction with FOXC2 (Fig. S4 C).
###end p 37
###begin p 38
###xml 0 49 0 49 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Location analysis of FOXC2-binding sites in LECs.</bold>
###xml 474 476 474 476 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">33</sup>
###xml 891 906 891 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib31">Ji et al., 2006</xref>
###xml 1415 1434 1411 1430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib72">Siepel et al., 2005</xref>
###xml 810 815 <span type="species:ncbi:9606">human</span>
Location analysis of FOXC2-binding sites in LECs. (A) Visualization of several FOXC2-binding regions. MAT score for each tiling array probe is shown in blue. Purple bars indicate FOXC2-enriched regions. Red peaks indicate ChIP regions selected for validation by EMSA. Potential target genes are indicated below the enrichment profile. Vertical lines, exons; horizontal lines, introns. Arrowheads indicate the direction of transcription. (B) Validation of ChIP-chip results. 33P-labeled 200-bp DNA probes from selected ChIP regions () were incubated with nuclear extracts from LECs transduced with FOXC2-expressing (AdFOXC2) or control adenovirus (AdLacZ), and the resulting DNA-protein complexes were analyzed by EMSA. GAPDH probe was used as a negative control. (C) Distribution of FOXC2-binding sites in the human genome. ChIP regions were mapped to their nearest RefSeq genes using CEAS (Ji et al., 2006). Proximal promoters and immediate downstream regions were defined as </=1 kb upstream from the transcription start site or </=1 kb downstream from the 3' end of a gene, respectively. Distal intergenic refers to all locations outside the boundaries of a gene and the 1 kb flanking the gene on either end. UTR, untranslated region. (D) FOXC2-binding regions are conserved among higher eukaryotes. ChIP regions were uniformly expanded to 3 kb, aligned at the center, and the mean phastCons conservation score (Siepel et al., 2005) was retrieved from the University of California Santa Cruz genome resource () for each aligned position. The mean phastCons score was plotted against the distance from ChIP region center (1.5 kb upstream and downstream). (E) Comparison of a novel FOXC2-binding motif identified by MEME analysis of ChIP-chip data with the Freac-3 (FOXC1) motif from the TRANSFAC database. The region of similarity is boxed. Chr, chromosome.
###end p 38
###begin p 39
###xml 193 201 193 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig9">Fig. 9 C</xref>
###xml 301 309 301 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig9">Fig. 9 D</xref>
Analysis of ChIP-chip data revealed that >90% of FOXC2-binding sites were located in distal intergenic regions and gene introns, and <1% of sites were located in the proximal promoter regions (Fig. 9 C). Notably, there was a high degree of conservation of FOXC2-binding sites among higher eukaryotes (Fig. 9 D), suggesting that the FOXC2-regulated transcriptional network in lymphatic vascular development is conserved across species.
###end p 39
###begin p 40
###xml 313 321 313 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig9">Fig. 9 E</xref>
###xml 470 489 470 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib68">Saleem et al., 2004</xref>
###xml 755 775 755 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib61">Pierrou et al., 1994</xref>
De novo motif discovery analysis revealed a common sequence motif in ChIP regions, which strongly resembled that of Freac-3 (FOXC1) from the TRANSFAC database. Both the newly discovered motif and the Freac-3 motif contained the 3'-terminal forkhead-binding element (T/A/C)AAACA preceded by an adenine-rich tract (Fig. 9 E). Such similarity between the two motifs is in good agreement with the fact that Freac-3/FOXC1 and FOXC2 have nearly identical DNA-binding domains (Saleem et al., 2004). The motifs, however, were completely different further upstream, which likely reflects fundamentally different approaches used for their identification. The Freac-3 motif has been identified by in vitro PCR selection using GST-tagged DNA-binding domain of FOXC1 (Pierrou et al., 1994), whereas the motif discovered in this study was derived from ChIP-chip experiments performed with endogenous FOXC2 in primary cells.
###end p 40
###begin p 41
###xml 595 604 595 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig10">Fig. 10 A</xref>
###xml 723 745 723 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib38">Khandekar et al., 2007</xref>
###xml 783 805 783 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib84">Wigle and Oliver, 1999</xref>
###xml 807 824 807 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib82">Wick et al., 2007</xref>
###xml 826 847 826 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">Francois et al., 2008</xref>
###xml 1410 1419 1398 1407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig10">Fig. 10 B</xref>
###xml 1680 1689 1668 1677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig10">Fig. 10 C</xref>
###xml 2637 2646 2625 2634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig10">Fig. 10 D</xref>
###xml 240 245 <span type="species:ncbi:9606">human</span>
We further studied whether the ChIP-chip data could suggest an explanation for the observed physical interaction of FOXC2 and NFATc1 as well as for their functional cooperation in the in vivo models. We performed enrichment analysis of all human transcription factor-binding sites from the TRANSFAC database in the FOXC2 ChIP sequences. NFAT-binding sites were significantly enriched (M00302, 2.07 fold change and 95% confidence interval [1.96; 2.19]; M00935, 1.95 fold change [1.84; 2.07]), whereas no statistically significant enrichment was seen for any of the control transcription factors (Fig. 10 A). Similarly, no enrichment was observed for transcription factors specifically expressed in endothelial cells (GATA2; Khandekar et al., 2007) or in LECs (SOX18, MEF2C, or PROX1; Wigle and Oliver, 1999; Wick et al., 2007; Francois et al., 2008; unpublished data). 86% of the FOXC2 ChIP sequences were found to contain at least one NFAT consensus sequence using a threshold of 3.4, which detects FOXC2-binding sites in 80% of the ChIP sequences (). Further experimental validation of the randomly selected approximately200-bp fragments from FOXC2 ChIP peak regions (Fig. S4 D) by EMSA revealed that NFATc1 strongly interacted with fragments 3, 4, 7, and 8 but not with fragments 1, 2, 5, 6, and 9. This observation was in agreement with the presence of NFAT consensus sites in the fragments 3, 4, 7, and 8 (Fig. 10 B; unpublished data). We next tested the fragments in luciferase reporter analysis and found that fragment 8 showed synergistic activation in the presence of both NFATc1 and FOXC2 compared with weak activation when either transcription factor was present alone (Fig. 10 C). Interestingly, the NFATc1-dependent activation of the reporter fragment 3 was partially repressed by FOXC2, whereas activity of reporter fragments 1 and 2 was not modified. The absence of response to FOXC2 of the reporters 1 and 2 could be a result of the fact that some 200-bp ChIP fragments may lack control elements needed for the efficient transcriptional regulation in our reporter system, or, alternatively, only the fragments that harbor both NFAT- and FOXC2-binding sites are capable of directing transcription. To investigate the mechanisms of transcriptional regulation by FOXC2 and NFATc1 in more detail, we performed site-directed mutagenesis of the reporter fragment 8, which contained three potential FOXC2-binding sites and one NFAT-binding site. Inactivation of FOXC2 site 1 proximal to the NFAT site significantly reduced the response to NFATc1, whereas mutations of more distal FOXC2 sites 2 and 3 had less pronounced effects (Fig. 10 D). These results suggest that FOXC2 binding is required for further reporter activation by NFATc1.
###end p 41
###begin p 42
###xml 0 42 0 42 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cooperation of FOXC2 and NFATc1 signaling.</bold>
###xml 531 533 531 533 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">33</sup>
Cooperation of FOXC2 and NFATc1 signaling. (A) Enrichment of FOXC2- and NFATc1-binding sites in ChIP sequences. Red points indicate the number of sites observed in the original ChIP sequences, showing that both FOXC2 (de novo-discovered matrix)- and NFAT (M00302 and M00935)-binding sites are highly enriched compared with the randomized sequences. PAX6 (M0097), CEBPB (M00109), ATF3 (M00513), BCL6 (M01183), and MYCMAX (M00322) are shown as examples of nonenriched sites. (B) NFATc1 interacts with a subset of FOXC2 ChIP regions. 33P-labeled DNA probes of approximately200 bp from selected ChIP peak regions () were incubated with recombinant NFATc1 protein together with anti-NFATc1 or control antibodies, and the resulting DNA-protein complexes were analyzed by EMSA. (C) Coregulation by FOXC2 and NFATc1. Selected approximately200-bp fragments of ChIP peak regions (Fig. S4 D) were subcloned into a pTA-luc luciferase reporter, and the luciferase activity was analyzed after cotransfection with either empty expression vector, expression vectors for FOXC2 or NFATc1, or both FOXC2 and NFATc1. (D) Mutations in FOXC2-binding sites reduce coactivation by NFATc1. Luciferase activity was analyzed after cotransfection of wild-type (WT) or mutated fragment 8/pTA-luc luciferase reporters with either empty expression vector, expression vectors for FOXC2 or NFATc1, or cotransfection with both FOXC2 and NFATc1. Data are presented as the mean +/- SD.
###end p 42
###begin p 43
In summary, we have identified FOXC2-binding sites in primary LECs using an unbiased genome-wide location mapping approach and showed that a subset of these regions is enriched in NFAT-binding sites. In addition, we demonstrated that NFATc1 and FOXC2 interact with ChIP-derived DNA and that these two transcription factors can cooperate in the regulation of transcription. Collectively, these data provide a molecular basis for the observed in vivo cooperation between the NFATc1 and FOXC2 signaling in the developing lymphatic vasculature.
###end p 43
###begin title 44
Discussion
###end title 44
###begin p 45
###xml 334 345 334 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib63">Risau, 1997</xref>
###xml 347 357 347 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">Jain, 2003</xref>
###xml 359 369 359 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib69">Sato, 2003</xref>
###xml 371 393 371 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">Davis and Senger, 2005</xref>
###xml 395 417 395 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">Chantrain et al., 2006</xref>
###xml 419 442 419 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib42">Lamont and Childs, 2006</xref>
Blood vessel maturation, which starts with establishment of the venous-arterial identity and continues with the remodeling by sprouting, splitting, fusion, and pruning of preexisting vessels, recruitment of mural cells, and the deposition of a basement membrane and a perivascular ECM, has been extensively studied over recent years (Risau, 1997; Jain, 2003; Sato, 2003; Davis and Senger, 2005; Chantrain et al., 2006; Lamont and Childs, 2006). However, much less is known about the corresponding developmental process in the lymphatic vasculature. In this study, we describe the morphological and molecular changes that lead to the formation of the collecting lymphatic vessels during development. We conclude that the transcription factors FOXC2 and NFATc1 control this process and are responsible for establishing a collecting lymphatic vessel identity by binding to proximal sites on the DNA and regulating expression of downstream genes.
###end p 45
###begin p 46
###xml 204 216 204 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib58">Oliver, 2004</xref>
###xml 218 238 218 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib47">Makinen et al., 2007</xref>
###xml 442 462 442 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib46">Makinen et al., 2005</xref>
###xml 1009 1031 1009 1031 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib86">Wirzenius et al., 2007</xref>
Discovery of lymphatic endothelial specific markers and molecular regulators, such as Prox1, VEGF-C-VEGFR-3, Foxc2, and LYVE-1, has significantly advanced our understanding of lymphatic vascular biology (Oliver, 2004; Makinen et al., 2007). In this study, we show that the specialization of lymphatic vessels into collecting vessels and capillaries is characterized by down-regulation of lymphatic capillary markers LYVE-1, VEGFR-3, and SLC (Makinen et al., 2005; and this study), which is preceded by changes in the expression pattern of the transcription factors Foxc2 and Prox1. The role of LYVE-1 and SLC down-regulation in collecting lymphatic vessel function remains to be investigated. In contrast, down-regulation of VEGFR-3 is likely to be important for the establishment of a quiescent phenotype of collecting lymphatic vessels, which act essentially as lymph conduits, whereas lymphatic capillaries continue to express high levels of VEGFR-3 and serve as primary sites of lymphangiogenic response (Wirzenius et al., 2007). Such balance in response to VEGF-C signaling would also be important to ensure maximally efficient lymph transport. Accumulation of ECM and basement membrane components, as well as recruitment of pericytes and SMCs, is a relatively late event in the establishment of a collecting vessel identity, which follows the changes in gene expression in the lymphatic endothelium. Interestingly, VEGFR-3, Prox1, and Foxc2 levels remain high in the developing and adult intraluminal valves, suggesting that valve LECs are molecularly distinct from the nearby cells in the collecting vessel trunk, perhaps as a result of distinct mechanosensory transduction in these two regions and the need for the constant repopulation of endothelial cells in the valves.
###end p 46
###begin p 47
###xml 145 150 145 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2</italic>
###xml 697 718 697 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">Gerhardt et al., 2003</xref>
###xml 828 833 828 833 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2</italic>
###xml 1361 1378 1358 1375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib87">Yang et al., 2000</xref>
###xml 1380 1397 1377 1394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib49">Mani et al., 2007</xref>
###xml 1380 1384 <span type="species:ncbi:156483">Mani</span>
###xml 1418 1422 <span type="species:ncbi:10090">mice</span>
Sharp up-regulation of Foxc2 at E15-15.5 is the earliest observed event during the formation of collecting vessels. Furthermore, genetic loss of Foxc2 leads to failure in the remodeling and the accompanying down-regulation of Prox1, VEGFR-3, LYVE-1, and SLC in maturing lymphatic vessels, which instead remain in an immature capillary-like state. Studies of the blood vasculature have demonstrated a functional separation of endothelial cells in angiogenic sprouts into stalk cells and tip cells, the latter characterized by extensive formation of filopodia, which is important for correct vessel guidance and establishment of a properly patterned vascular network in response to a VEGF gradient (Gerhardt et al., 2003). In this study, we show that in spite of excessive VEGFR-3 expression and lymphatic vessel hyperplasia, the Foxc2-deficient capillary plexus is paradoxically characterized by defective sprouting. Although the exact cause remains to be investigated, this is possibly a result of abnormal deposition of collagen IV around nascent tip cells, which could prevent formation of tip cell filopodia and normal vessel guidance and patterning. An important remaining question concerns the signals controlling Foxc2 expression in the developing lymphatic vasculature; studies from other cell types show that TGF-beta or BMP2 can induce FOXC2 in vitro (Yang et al., 2000; Mani et al., 2007). Future studies of mice with conditional ablation of TGF or bone morphogenetic proteins signaling components in the lymphatic endothelium should clarify the contribution of these pathways to Foxc2 regulation.
###end p 47
###begin p 48
###xml 1080 1102 1080 1102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib66">Saaristo et al., 2002b</xref>
###xml 1104 1126 1104 1126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib86">Wirzenius et al., 2007</xref>
###xml 1260 1282 1260 1282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib86">Wirzenius et al., 2007</xref>
In search of similarities between the molecular mechanisms of cardiac and lymphatic valve formation, we found that NFATc1, a transcription factor that controls the morphogenesis of cardiac valves, is expressed in the developing lymphatic vasculature and intraluminal valves. Our data from primary LECs show that PROX1, at least in part, controls the LEC-specific expression of NFATc1, whereas the lymphangiogenic growth factor VEGF-C induces NFATc1 nuclear translocation through activation of VEGFR-2. The relative extent of the contribution of VEGFR-2-VEGFR-2 homodimeric versus VEGFR-2-VEGFR-3 heterodimeric complexes to NFATc1 activation remains to be determined; however, the inability of VEGFR-3 signaling alone to activate NFATc1 nuclear translocation suggests that in the lymphatic endothelium VEGFR-2- or VEGFR-2-VEGFR-3-mediated pathways are more important for the establishment of collecting vessel phenotype rather than for the formation of a capillary network. In agreement with this hypothesis, VEGFR-2 is highly expressed in collecting lymphatic vessels and valves (Saaristo et al., 2002b; Wirzenius et al., 2007; unpublished data) where it promotes lymphatic vessel enlargement, whereas VEGFR-3 signaling is responsible for capillary sprouting (Wirzenius et al., 2007).
###end p 48
###begin p 49
###xml 265 288 265 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib70">Schulz and Yutzey, 2004</xref>
###xml 305 329 305 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">Crabtree and Olson, 2002</xref>
###xml 355 361 355 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Nfatc1</italic>
###xml 892 897 892 897 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2</italic>
###xml 897 900 897 900 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 946 951 946 951 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2</italic>
###xml 1128 1133 1128 1133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2</italic>
###xml 372 376 <span type="species:ncbi:10090">mice</span>
###xml 901 905 <span type="species:ncbi:10090">mice</span>
###xml 1045 1049 <span type="species:ncbi:10090">mice</span>
###xml 1144 1148 <span type="species:ncbi:10090">mice</span>
In addition to its role in endocardial cells, NFAT signaling in the blood vascular endothelium is important for cell proliferation, expression of proinflammatory genes, vascular patterning during early embryogenesis, and angiogenesis under pathological conditions (Schulz and Yutzey, 2004; for review see Crabtree and Olson, 2002). Our in vivo data, from Nfatc1-deficient mice and after inhibition of NFAT activation by CsA, show that the calcineurin/NFAT pathway does not contribute to angiogenesis at late stages of embryonic development, nor does it affect LEC commitment. Instead, loss of NFAT signaling impairs the maturation and remodeling of the lymphatic vasculature as indicated by persistent expression of lymphatic capillary markers, lymphatic vessel hyperplasia, reduced formation of lymphatic valves, and impaired sprouting. These phenotypes, reminiscent of the ones observed in Foxc2-/- mice, are strongly enhanced upon loss of one Foxc2 allele, suggesting a genetic interaction between these two pathways. However, in CsA-treated mice, Foxc2 expression is high in all LECs, whereas NFATc1 expression is normal in Foxc2-deficient mice. These results indicate that Foxc2 and NFATc1 are expressed independently of each other and suggest that they act by coregulating transcription of downstream genes.
###end p 49
###begin p 50
###xml 263 286 263 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib23">Hayashi and Kume, 2008a</xref>
###xml 287 288 287 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib24">b</xref>
###xml 290 310 290 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib25">Hayashi et al., 2008</xref>
###xml 631 651 627 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">Carroll et al., 2005</xref>
###xml 653 672 649 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib43">Lupien et al., 2008</xref>
###xml 1384 1389 1380 1385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2</italic>
###xml 1523 1537 1519 1533 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Xenopus laevis</italic>
###xml 1510 1519 <span type="species:ncbi:7955">zebrafish</span>
###xml 1523 1537 <span type="species:ncbi:8355">Xenopus laevis</span>
To gain mechanistic understanding of the role of FOXC2 in LECs, we performed a genome-wide analysis of FOXC2-binding sites. Previous studies suggested several FOXC2 target genes in blood vascular endothelium based on computational analysis of proximal promoters (Hayashi and Kume, 2008a,b; Hayashi et al., 2008). In this report, we have studied the association of FOXC2 across the entire genome, and we show that the vast majority of FOXC2-binding sites are located in the intergenic and intronic regions, arguing that FOXC2 acts primarily via distal enhancers as previously observed for estrogen-related receptor alpha and FOXa1 (Carroll et al., 2005; Lupien et al., 2008). The analysis of FOXC2 ChIP sequences demonstrated that NFAT-binding sites are strongly enriched in the proximity of FOXC2-binding sites. Based on this observation, we experimentally confirmed that NFATc1 binds to FOXC2 ChIP-derived fragments containing NFAT consensus and that it can direct transcription in reporter assays, thus providing the molecular basis for the NFAT and FOXC2 cooperation in vivo. The outstanding remaining question concerns the identification of FOXC2/NFATc1 effector genes or pathways responsible for establishment of the lymphatic collecting vessel phenotype. Future studies, including the combination of ChIP-chip data with chromosome capture analysis, gene expression profiling of Foxc2-deficient LECs, and large-scale screening studies in small vertebrate models of lymphatic vascular development, such as zebrafish or Xenopus laevis, will be invaluable to answer these questions.
###end p 50
###begin p 51
###xml 627 632 627 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2</italic>
In conclusion, our data provide a new understanding of the developmental regulation of lymphatic vessels and the role of Foxc2 in establishing a collecting vessel identity and introduce a novel role for the transcription factor NFATc1 in lymphatic development. Based on our findings, we propose a model for the role of Foxc2 and NFATc1 in establishing the identity of collecting lymphatic vessels. During normal lymphatic development, maturing lymphatic vessels up-regulate Foxc2, and VEGF-C-VEGFR-2/3 signaling activates NFATc1, which together start a genetic program for formation of collecting vessels. Deficiency in either Foxc2 or active NFATc1 in the lymphatic endothelium affects the expression of target genes, shutting down the program for establishment of a collecting vessel identity and leading to a persistent capillary-like phenotype. As damage to collecting vessels is a leading cause of secondary lymphedema, which frequently develops after cancer surgery-associated lymph node dissection, our data suggest that therapeutic delivery of FOXC2 and constitutively active NFATc1 could represent a strategy for treatment of secondary lymphedema through enhanced regeneration of collecting lymphatic vessels.
###end p 51
###begin title 52
Materials and methods
###end title 52
###begin title 53
Animal models and in vivo analyses
###end title 53
###begin p 54
###xml 142 145 142 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 137 145 137 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxc2<sup>&#8722;/&#8722;</sup></italic>
###xml 222 239 222 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib28">Iida et al., 1997</xref>
###xml 241 261 241 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib59">Petrova et al., 2004</xref>
###xml 270 273 270 273 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 264 273 264 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NFATc1<sup>&#8722;/&#8722;</sup></italic>
###xml 281 287 281 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/lacZ</sup>
###xml 275 287 275 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Angpt2<sup>+/lacZ</sup></italic>
###xml 352 371 352 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib62">Ranger et al., 1998</xref>
###xml 373 397 373 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">DasGupta and Fuchs, 1999</xref>
###xml 399 416 399 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">Gale et al., 2002</xref>
###xml 418 438 418 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib50">Maretto et al., 2003</xref>
###xml 146 150 <span type="species:ncbi:10090">mice</span>
###xml 297 301 <span type="species:ncbi:10090">mice</span>
###xml 315 319 <span type="species:ncbi:10090">mice</span>
###xml 482 486 <span type="species:ncbi:10090">mice</span>
###xml 508 512 <span type="species:ncbi:10090">mice</span>
###xml 643 647 <span type="species:ncbi:10090">mice</span>
Animal experiments were approved by the National Animal Ethics Committee and were performed in accordance with institutional guidelines. Foxc2-/- mice were bred on the ICR background and genotyped as described previously (Iida et al., 1997; Petrova et al., 2004). NFATc1-/-, Angpt2+/lacZ, TOP-Gal mice, and BAT-Gal mice have been described previously (Ranger et al., 1998; DasGupta and Fuchs, 1999; Gale et al., 2002; Maretto et al., 2003). For experiments involving only wild-type mice, outbred ICR or NMRI mice were used. Embryonic age was determined according to the day of the vaginal plug (E0.5). For NFAT inhibition, E12.5-16.5 pregnant mice were given 50 mg/kg CsA (EMD) in 10% DMSO in sunflower seed oil (Sigma-Aldrich) or DMSO in oil only twice a day by oral gavage.
###end p 54
###begin p 55
For fluorescent lymphangiography, embryos were injected with 10 mg/ml FITC-dextran in PBS (2,000-kD molecular mass; Sigma-Aldrich) subcutaneously in the hind limbs immediately after dissection, and flank collecting lymphatic vessels were visualized by fluorescence microscopy.
###end p 55
###begin title 56
Antibodies, staining procedures, and image acquisition
###end title 56
###begin p 57
###xml 119 141 119 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib65">Saaristo et al., 2002a</xref>
###xml 143 163 143 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib75">Tammela et al., 2005</xref>
###xml 447 468 443 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">Furumoto et al., 1999</xref>
###xml 539 561 535 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib77">Timmerman et al., 1997</xref>
###xml 589 612 585 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib35">Karkkainen et al., 2004</xref>
###xml 680 700 676 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib59">Petrova et al., 2004</xref>
###xml 388 394 <span type="species:ncbi:9793">donkey</span>
###xml 425 428 <span type="species:ncbi:10116">rat</span>
###xml 434 439 <span type="species:ncbi:10090">mouse</span>
###xml 471 476 <span type="species:ncbi:10090">mouse</span>
###xml 482 487 <span type="species:ncbi:9606">human</span>
###xml 564 570 <span type="species:ncbi:9986">rabbit</span>
###xml 576 581 <span type="species:ncbi:9606">human</span>
###xml 615 619 <span type="species:ncbi:9925">goat</span>
###xml 625 630 <span type="species:ncbi:10090">mouse</span>
###xml 654 660 <span type="species:ncbi:9986">rabbit</span>
###xml 666 671 <span type="species:ncbi:10090">mouse</span>
###xml 703 706 <span type="species:ncbi:10116">rat</span>
###xml 712 717 <span type="species:ncbi:10090">mouse</span>
###xml 732 738 <span type="species:ncbi:9986">rabbit</span>
###xml 744 749 <span type="species:ncbi:10090">mouse</span>
###xml 782 787 <span type="species:ncbi:10090">mouse</span>
###xml 793 798 <span type="species:ncbi:9606">human</span>
###xml 826 832 <span type="species:ncbi:9986">rabbit</span>
###xml 838 843 <span type="species:ncbi:10090">mouse</span>
###xml 873 877 <span type="species:ncbi:9925">goat</span>
###xml 883 888 <span type="species:ncbi:10090">mouse</span>
Mesenteries and skins were dissected, fixed in 4% PFA, and whole-mount staining was performed as described previously (Saaristo et al., 2002a; Tammela et al., 2005). 6-microm deparaffinized tissue sections were subjected to heat-induced epitope retrieval (High pH Retrieval Solution; Dako). Cultured cells were fixed with 4% PFA, permeabilized with 0.1% Triton X-100, and blocked with 5% donkey serum. For stainings, we used rat anti-mouse Foxc2 (Furumoto et al., 1999), mouse anti-human NFATc1 (clone 7A6; Santa Cruz Biotechnology, Inc.; Timmerman et al., 1997), rabbit anti-human PROX1 (Karkkainen et al., 2004), goat anti-mouse VEGFR-3 (R&D Systems), rabbit anti-mouse LYVE-1 (Petrova et al., 2004), rat anti-mouse PECAM-1 (BD), rabbit anti-mouse NG2 (Millipore), Cy3-conjugated mouse anti-human alpha-SMA (Sigma-Aldrich), rabbit anti-mouse collagen IV (Cosmo Bio), and goat anti-mouse SLC (R&D Systems). Alexa Fluor 488, 594, and 647 fluorochrome-conjugated secondary antibodies (Invitrogen) were used for signal detection. The tyramide signal amplification method (Tyramide Signal Amplification Indirect; PerkinElmer) was used for the detection of VEGFR-3 after in situ hybridization.
###end p 57
###begin p 58
Samples were mounted with DAPI-containing Vectashield (Vector Laboratories) and analyzed at room temperature with a confocal microscope (LSM 510 Meta; Carl Zeiss, Inc.) using LSM AIM software or an epifluorescent microscope (Axioplan 2; Carl Zeiss, Inc.) equipped with a charge-coupled device camera (AxioCam HRc; Carl Zeiss, Inc.) using Axiovision software (version 4.6; Carl Zeiss, Inc.). Objectives used were 10x Plan-Apochromat NA 0.45, 10x Fluar NA 0.5, 10x Plan-Neofluar NA 0.3, 20x Plan-Neofluar NA 0.5, 40x Plan-Apochromat NA 1.3, 40x long-distance C-Apochromat NA 1.1, and 40x Plan-Neofluar NA 0.75 (Carl Zeiss, Inc.). Three-dimensional projections of whole-mount images were digitally reconstructed from confocal z stacks using LSM AIM software and processed using Photoshop (CS; Adobe). Images are representative pictures from three to five embryos/stage or phenotype.
###end p 58
###begin title 59
In situ hybridization
###end title 59
###begin p 60
###xml 111 126 111 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib85">Wilkinson, 1998</xref>
###xml 208 214 208 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Angpt2</italic>
###xml 271 277 271 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NFATc1</italic>
###xml 342 347 342 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prox1</italic>
Frozen sections or whole-mount mesenteries from E17.5 embryos were used and processed as described previously (Wilkinson, 1998). Sections were hybridized with complementary RNA anti-sense or sense probes for Angpt2 (nucleotides 45-738 from GenBank under accession no. ), NFATc1 (nucleotides 1,012-1,519 from GenBank under accession no. ), or Prox1 (nucleotides 276-1,208 from GenBank under accession no. ).
###end p 60
###begin title 61
Cell culture, transfections, transductions, and luciferase reporter assays
###end title 61
###begin p 62
###xml 51 73 51 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib22">Haraldsen et al., 1995</xref>
###xml 75 95 75 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib29">Jahnsen et al., 1997</xref>
###xml 416 437 408 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib36">Karpanen et al., 2006</xref>
###xml 478 498 462 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib26">Heckman et al., 2008</xref>
###xml 527 548 511 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">Gerhardt et al., 2003</xref>
###xml 1009 1029 993 1013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib60">Petrova et al., 2002</xref>
###xml 1039 1059 1023 1043 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib59">Petrova et al., 2004</xref>
###xml 1071 1092 1055 1076 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib41">Laitinen et al., 1998</xref>
###xml 1408 1432 1392 1416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib54">Monticelli and Rao, 2002</xref>
###xml 1442 1462 1426 1446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib59">Petrova et al., 2004</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 996 1001 <span type="species:ncbi:9606">human</span>
Human iLECs were isolated as described previously (Haraldsen et al., 1995; Jahnsen et al., 1997) and cultured in endothelial cell growth medium (PromoCell). Lymphatic endothelial identity was confirmed with PROX1 staining. For growth factor treatments, iLECs were starved for 6 h, treated with 200 ng/ml CsA (EMD) in DMSO or only DMSO for 2 h in starvation medium, and stimulated with 200 ng/ml DeltaNDeltaC VEGF-C (Karpanen et al., 2006), 500 ng/ml DeltaNDeltaC VEGF-C(C156S) (Heckman et al., 2008), and 500 ng/ml VEGF-E NZ7 (Gerhardt et al., 2003) for 20 min. For siRNA experiments, iLECs were transfected with 10-40 nM siRNA using Lipofectamine 2000 (Invitrogen) and the following siRNAs: PROX1, 5'-CUAUGAGCCAGUUUGAUAUUU-3' (Thermo Fisher Scientific); FOXC2, 5'-AGGTGGTGATCAAGAGCGAUU-3'; or siRNA Allstars Control (Invitrogen). Cells were lysed 48-96 h after transfection. For adenoviral experiments, iLECs were transduced with 20-50 plaque-forming unit/cell recombinant adenoviruses encoding human PROX1 (Petrova et al., 2002), FOXC2 (Petrova et al., 2004), or LacZ (Laitinen et al., 1998) in serum-free medium for 1 h and lysed 48 h after transfection. For luciferase reporter assays, 183-199-bp sequences from selected ChIP peak regions were subcloned into pTA luciferase reporter vector. 293T cells were cotransfected with reporter constructs and constitutively active NFATc1 (plasmid 11102; Addgene; Monticelli and Rao, 2002), FOXC2 (Petrova et al., 2004), and empty vectors using jetPEI transfection reagent (Polyplus-Transfection). Renilla luciferase pCMV-RL (provided by C. Heckman, University of Helsinki, Helsinki, Finland) was used for normalization of transfection efficiency. 48 h after transfection, cells were lysed and analyzed using Dual-Luciferase kit (Promega). Mutations in FOXC2-binding sites in fragment 8 were introduced using site-directed mutagenesis with the following primers: NFAT mutant, 5'-CAAAAACACACTCCAACCTTTCC-3' and 5'-GATGTAGGTCTAAGGGCGAATTC-3'; FOXC2 mutant 1, 5'-GACAGAAACCTATTATTGGAAACAATT-3' and 5'-CGTTCAGGGTAGGAGAAGGGAAG-3'; FOXC2 mutant 2, 5'-GACAGGATTCATATATTTCATCC-3' and 5'-CATAGACGTGTATGAAATAATTGTT-3'; and FOXC2 mutant 3, 5'-GACATGTCAAAATAGGAAGCCCA-3' and 5'-CTTATTTCCTGGATGAAATATATGAATCCTGT-3'. The presence of mutations was verified by sequencing. Experiments were done in triplicate and repeated at least three times. Values are expressed as fold increase compared with empty control +/- SD.
###end p 62
###begin title 63
ChIP-chip analysis
###end title 63
###begin p 64
###xml 52 73 52 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib56">O'Geen et al., (2006)</xref>
###xml 420 441 420 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">Furumoto et al., 1999</xref>
###xml 1101 1121 1101 1121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib33">Johnson et al., 2006</xref>
###xml 1630 1645 1630 1645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib31">Ji et al., 2006</xref>
###xml 389 392 <span type="species:ncbi:10116">rat</span>
###xml 398 403 <span type="species:ncbi:10090">mouse</span>
###xml 1010 1015 <span type="species:ncbi:9606">Human</span>
ChIP-chip was performed essentially as described by O'Geen et al., (2006) with the following modifications: iLECs were cross-linked with formaldehyde in complete endothelial cell basal medium MV (PromoCell), and IP dilution buffer was substituted with 3% BSA containing complete inhibitor tablets (Roche). DNA was sheared using a sonicator (Soniprep 150; MSE) and immunoprecipitated using rat anti-mouse Foxc2 antibody (Furumoto et al., 1999) complexed with protein G-Sepharose (GE Healthcare). Decross-linked ChIP DNA was amplified using GenomePlex Complete Whole Genome Amplification kit (Sigma-Aldrich) using the buffer supplemented with deoxynucleotide-triphosphate + deoxy-UTP mixture. DNA was fragmented using uracil DNA glycosylase and apurinic/apyrimidinic endonuclease. Terminal labeling, hybridization, and array processing were performed as recommended by the array manufacturer (Affymetrix). Three biologically independent ChIP replicates and two control IgG replicates were hybridized to GeneChip Human Tiling 2.0R Array Sets (Affymetrix). Data analysis was performed using MAT software (Johnson et al., 2006) at 0.1% FDR cutoff (intensity analysis parameters: BandWidth = 300, MaxGap = 300, MinProbe = 10). A total of 2,359 FOXC2-enriched regions were identified of which nine mitochondrial sequences were discarded from further analysis. Enriched regions were visualized using Integrated Genome Browser software (Affymetrix). Initial analyses of evolutionary conservation, nearby genes, and enriched transcription factor-binding motifs were performed using cis-regulatory element annotation system (CEAS) software (Ji et al., 2006).
###end p 64
###begin title 65
Bioinformatics analyses of ChIP-chip data
###end title 65
###begin p 66
###xml 415 437 415 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib2">Bailey and Elkan, 1994</xref>
###xml 572 593 572 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib76">Thompson et al., 2003</xref>
400-bp-long fragments from the center of each ChIP sequence were extracted and ranked according to the p-value. The fragments were split in 10 bins of 235 sequences each, with bin 1 containing the sequences with the lowest p-values and bin 10 containing the sequences with the highest p-values. De novo motif discovery was performed in each bin separately using the program MEME (multiple EM for motif elicitation; Bailey and Elkan, 1994) in the mode of one occurrence per sequence and a motif width ranging from 7 to 15. MEME results were confirmed by the Gibbs sampler (Thompson et al., 2003) with default options.
###end p 66
###begin p 67
###xml 125 143 125 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib51">Matys et al., 2003</xref>
###xml 192 199 192 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pftools</italic>
###xml 209 228 209 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">Bucher et al., 1996</xref>
###xml 230 249 230 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib64">Roulet et al., 2002</xref>
###xml 761 777 761 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib37">Kel et al., 1999</xref>
###xml 1451 1474 1451 1474 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila melanogaster</italic>
###xml 1494 1513 1494 1513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">Choksi et al., 2006</xref>
###xml 1451 1474 <span type="species:ncbi:7227">Drosophila melanogaster</span>
The de novo-discovered FOXC2-binding site and all vertebrate transcription factor-binding sites stored as TRANSFAC matrices (Matys et al., 2003) were turned into calibrated profiles using the pftools program (Bucher et al., 1996; Roulet et al., 2002). To select a stringency threshold defining binding site predictions of high quality, several score thresholds were applied to detect potential FOXC2-binding sites in the 2,350 ChIP sequences, and the threshold of 3.4 was selected, as it predicted a FOXC2-binding site in 80% of the sequences. This same threshold was then used to predict the positions of other transcription factor-binding sites such as NFAT. The NFAT matrix 1 has been derived from 26 experimentally identified endogenous NFAT-binding sites (Kel et al., 1999), and the NFAT matrix 2 has been derived from a selection of the same sites used for matrix 1 plus eight additional TRANSCompel sites. The same 3.4 cutoff was used to compute random matches in 1,000 random sets, which were composed of randomly shuffled ChIP sequences with a window of 20 nucleotides. The enrichment, or fold change, was computed as the ratio of the number of ChIP matches and the mean number of random matches. The 95% confidence interval for the enrichment ratios was estimated assuming that the sampling distribution is approximately Gaussian for the log ratio and Poisson for the counts. For the analysis of putative PROX1-binding sites, the matrix for Drosophila melanogaster prospero was used (Choksi et al., 2006).
###end p 67
###begin title 68
EMSA
###end title 68
###begin p 69
###xml 107 108 103 104 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 218 220 210 212 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">33</sup>
###xml 284 289 <span type="species:ncbi:9606">human</span>
###xml 345 348 <span type="species:ncbi:10116">rat</span>
###xml 354 359 <span type="species:ncbi:10090">mouse</span>
###xml 367 372 <span type="species:ncbi:10090">mouse</span>
###xml 378 383 <span type="species:ncbi:9606">human</span>
25 microl EMSA reaction mixtures contained 10 mM Hepes, pH 8.0, 3 mM Tris-HCl, pH 8.0, 50 mM KCl, 2 mM MgCl2, 10% glycerol, 1 mM dithiotreitol, 0.04 mg/ml poly-deoxy-inosinic-deoxy-cytidylic acid, 0.4 mg/ml BSA, gamma-33P-labeled DNA probe, and cell lysates or 0.8 microg recombinant human NFATc1 protein (SignalChem). For supershifts, 1 microg rat anti-mouse Foxc2, mouse anti-human NFATc1, or control antibodies from the same species were added to the reaction mixtures. After incubation for 30 min at room temperature, probes were loaded on 5% criterion Tris-Borate-EDTA polyacrylamide gel (Bio-Rad Laboratories). Electrophoresis was performed for 1-2 h at 10-20 mA/100-150 V. The gels were dried and visualized by autoradiography or using a phosphorimager.
###end p 69
###begin title 70
Immunoprecipitation and Western and Northern blotting
###end title 70
###begin p 71
###xml 481 487 <span type="species:ncbi:9986">rabbit</span>
For analysis of protein interaction, 293T cells were cotransfected with HA-NFATc1 and FOXC2 expression vectors using Lipofectamine 2000 (Invitrogen). 48 h after transfection, cells were lysed with buffer containing 20 mM Tris, pH 7.8, 500 nM NaCl, 1% NP-40, and complete protease inhibitor mixture (Roche). The lysates were sonicated, spinned down, precleared with protein G-Sepharose beads (GE Healthcare), incubated overnight with anti-HA antibodies (Abcam) or control nonimmune rabbit IgG (Sigma-Aldrich), and incubated with protein G-Sepharose beads. The precipitates were washed with lysis buffer, resuspended in Laemmli sample buffer, and heated at 95degreesC for 10 min.
###end p 71
###begin p 72
###xml 162 183 162 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">Furumoto et al., 1999</xref>
For Western blotting, samples were resolved by SDS-PAGE, transferred onto Immobilon-P membrane (Millipore), and blotted with monoclonal antibodies against Foxc2 (Furumoto et al., 1999), NFATc1 (clone 7A6; Santa Cruz Biotechnology, Inc.), PROX1 (R&D Systems), phospho-VEGFR-2 (Tyr1175; Cell Signaling Technology), phospho-ERK1/2 (Cell Signaling Technology), and GAPDH (Europa Bioproducts). Western blots were developed using the ECL method (SuperSignal West Femto Maximum Sensitivity Substrate; Thermo Fisher Scientific).
###end p 72
###begin p 73
###xml 153 155 149 151 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 183 189 179 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NFATc1</italic>
###xml 177 182 <span type="species:ncbi:9606">human</span>
For Northern analysis, 10 microg total RNA was separated in a 1% agarose gel, and blots were hybridized in ULTRAhyb solution (Applied Biosystems) with a 32P-labeled fragment of human NFATc1 (nucleotides 2,577-2,825 from GenBank under accession no. ).
###end p 73
###begin title 74
Quantification and statistical analysis
###end title 74
###begin p 75
###xml 115 116 115 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 208 209 208 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 902 903 902 903 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
Mesenteric valves were identified as areas of strongly positive Prox1 staining and counted from duodenum to ileum (n = 4 for each genotype and treatment; E17.5). The mean vessel widths of dermal capillaries (n = 4) were calculated using Matlab (Mathworks) by dividing vessel area (determined by thresholding) by length (determined by a skeletonization algorithm by Nicholas R. Howe, Smith College, Northampton, MA). For colocalization of Foxc2 and NFATc1, LECs were counted from nine different lymphatic vessels from paraffin sections of three wild-type E17.5 embryos. For analysis of nuclear NFATc1 intensity in LECs, RGB images were analyzed with the CellCounter program (developed by V. Rantanen, Molecular Imaging Unit, University of Helsinki). Values were counted from nuclear NFATc1 staining and expressed as mean percentual intensity of maximum pixel intensity. A two-tailed, unpaired Student's t test was performed to determine statistical significance by the probability of difference between the means.
###end p 75
###begin title 76
Online supplemental material
###end title 76
###begin p 77
###xml 201 207 201 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NFATc1</italic>
###xml 455 461 455 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NFATc1</italic>
###xml 59 64 <span type="species:ncbi:10090">mouse</span>
###xml 352 356 <span type="species:ncbi:10090">mice</span>
Fig. S1 shows LEC clusters and filopodia in the developing mouse mesentery at E14.5 and heterogeneous expression of LYVE-1 in embryonic mesentery and skin during development. Fig. S2 shows analysis of NFATc1 expression by in situ hybridization, colocalization with Foxc2, inhibition of NFATc1 nuclear translocation, and Foxc2 expression in CsA-treated mice. Fig. S3 shows activation of ERK1/2 phosphorylation by wild-type and mutant growth factors, equal NFATc1 mRNA levels in iLECs after growth factor stimulation, and an increase in overall NFATc1 expression upon PROX1 overexpression, coimmunoprecipitation of FOXC2, and NFATc1. Fig. S4 shows Western blots of FOXC2 ChIP experiments, binding of FOXC2 to ChIP targets in EMSA, which is abolished by mutations in FOXC2-binding sites, and a table with ChIP region fragments used in EMSAs and luciferase reporter assays. The supplemental data contains the CEAS annotation results of all FOXC2 ChIP sequences, whereas Table S1 shows FOXC2 ChIP regions that also were found to contain NFAT-binding sites. Online supplemental material is available at .
###end p 77
###begin title 78
Supplementary Material
###end title 78
###begin title 79
[Supplemental Material Index]
###end title 79
###begin p 80
###xml 140 143 140 143 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 134 143 134 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NFATc1<sup>&#8722;/&#8722;</sup></italic>
###xml 259 262 259 262 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 253 262 253 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NFATc1<sup>&#8722;/&#8722;</sup></italic>
###xml 340 344 <span type="species:ncbi:10090">mice</span>
We thank Dr. Elaine Fuchs and Dr. Nicole Stokes (Howard Hughes Medical Institute, The Rockefeller University, New York, NY) for E15.5 NFATc1-/- embryos, Drs. Gerald Crabtree and Wen Qi Ho (Stanford University School of Medicine, Stanford, CA) for E12.5 NFATc1-/- embryos, Dr. Stefano Piccolo (University of Padua, Padua, Italy) for BAT-Gal mice, Dr. Michael Jeltsch (University of Helsinki) for VEGF-C and VEGF-E proteins, Dr. Caroline Heckman (University of Helsinki) for the pCMV-RL luciferase plasmid, and Dr. Ernest Mueller from Sigma-Aldrich for the custom-formulated WGA buffer. We gratefully acknowledge Alun Parsons, Tapio Tainola, Sanna Wallin, Kaisa Makkonen, Sanna Lampi, Paula Hyvarinen, and Mari Helantera for technical support, the Biomedicum Helsinki Molecular Imaging Unit and Ville Rantanen for technical assistance on imaging and image analysis, and Outi Monni and Hanna Pesonen for help in microarray processing. Microarray hybridization was carried out at Biomedicum Biochip Center.
###end p 80
###begin p 81
The study was supported by the Academy of Sciences of Finland, Sigrid Juselius Foundation, Swiss National Science Foundation, Magnus Ehrnrooth Foundation, Louis-Jeantet Foundation, European Union (Lymphangiogenomics project no. LSHG-CT-2004-503573), K. Albin Johansson Foundation, Helsinki Biomedical Graduate School, Nylands Nation, Einar and Karin Stroem's Foundation, Svenska Kulturfonden, Biomedicum Helsinki Foundation, Medicinska Understodsforeningen Liv och Halsa, Paulos Foundation, Orion-Farmos Research Foundation, and Deutsche Forschungsgemeinschaft (SFB-TR23 A3 Vascular Differentiation and Remodeling grant to H.G. Augustin).
###end p 81
###begin article-title 82
Heart valve development: endothelial cell signaling and differentiation.
###end article-title 82
###begin article-title 83
Fitting a mixture model by expectation maximization to discover motifs in biopolymers.
###end article-title 83
###begin article-title 84
Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells.
###end article-title 84
###begin article-title 85
###xml 84 92 <span type="species:ncbi:9606">patients</span>
Analysis of the phenotypic abnormalities in lymphoedema-distichiasis syndrome in 74 patients with FOXC2 mutations or linkage to 16q24.
###end article-title 85
###begin article-title 86
A flexible motif search technique based on generalized profiles.
###end article-title 86
###begin article-title 87
Intussusceptive angiogenesis: its emergence, its characteristics, and its significance.
###end article-title 87
###begin article-title 88
Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1.
###end article-title 88
###begin article-title 89
A field of myocardial-endocardial NFAT signaling underlies heart valve morphogenesis.
###end article-title 89
###begin article-title 90
Mechanisms of pericyte recruitment in tumour angiogenesis: a new role for metalloproteinases.
###end article-title 90
###begin article-title 91
###xml 77 87 77 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
Prospero acts as a binary switch between self-renewal and differentiation in Drosophila neural stem cells.
###end article-title 91
###begin article-title 92
NFAT signaling: choreographing the social lives of cells.
###end article-title 92
###begin article-title 93
Multiple roles for activated LEF/TCF transcription complexes during hair follicle development and differentiation.
###end article-title 93
###begin article-title 94
Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization.
###end article-title 94
###begin article-title 95
Role of the NF-ATc transcription factor in morphogenesis of cardiac valves and septum.
###end article-title 95
###begin article-title 96
###xml 93 97 <span type="species:ncbi:10090">mice</span>
Defective remodeling and maturation of the lymphatic vasculature in Angiopoietin-2 deficient mice.
###end article-title 96
###begin article-title 97
###xml 26 31 <span type="species:ncbi:10090">mouse</span>
Cardiovascular failure in mouse embryos deficient in VEGF receptor-3.
###end article-title 97
###begin article-title 98
###xml 58 62 <span type="species:ncbi:10090">mice</span>
Sox18 induces development of the lymphatic vasculature in mice.
###end article-title 98
###begin article-title 99
Notochord-dependent expression of MFH1 and PAX1 cooperates to maintain the proliferation of sclerotome cells during the vertebral column development.
###end article-title 99
###begin article-title 100
Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1.
###end article-title 100
###begin article-title 101
VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia.
###end article-title 101
###begin article-title 102
Signals transduced by Ca(2+)/calcineurin and NFATc3/c4 pattern the developing vasculature.
###end article-title 102
###begin article-title 103
###xml 34 39 <span type="species:ncbi:9606">human</span>
Isolation and longterm culture of human intestinal microvascular endothelial cells.
###end article-title 103
###begin article-title 104
Forkhead transcription factors regulate expression of the chemokine receptor CXCR4 in endothelial cells and CXCL12-induced cell migration.
###end article-title 104
###begin article-title 105
Foxc transcription factors directly regulate Dll4 and Hey2 expression by interacting with the VEGF-Notch signaling pathways in endothelial cells.
###end article-title 105
###begin article-title 106
The Foxc2 transcription factor regulates angiogenesis via induction of integrin beta3 expression.
###end article-title 106
###begin article-title 107
The tyrosine kinase inhibitor cediranib blocks ligand-induced VEGFR-3 activity and lymphangiogenesis.
###end article-title 107
###begin article-title 108
NFATc1 balances quiescence and proliferation of skin stem cells.
###end article-title 108
###begin article-title 109
Essential roles of the winged helix transcription factor MFH-1 in aortic arch patterning and skeletogenesis.
###end article-title 109
###begin article-title 110
Expression of functional VCAM-1 by cultured nasal polyp-derived microvascular endothelium.
###end article-title 110
###begin article-title 111
Molecular regulation of vessel maturation.
###end article-title 111
###begin article-title 112
CEAS: cis-regulatory element annotation system.
###end article-title 112
###begin article-title 113
###xml 76 81 <span type="species:ncbi:9606">human</span>
NFATc1 mediates vascular endothelial growth factor-induced proliferation of human pulmonary valve endothelial cells.
###end article-title 113
###begin article-title 114
Model-based analysis of tiling-arrays for ChIP-chip.
###end article-title 114
###begin article-title 115
A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities.
###end article-title 115
###begin article-title 116
Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins.
###end article-title 116
###begin article-title 117
Functional interaction of VEGF-C and VEGF-D with neuropilin receptors.
###end article-title 117
###begin article-title 118
Recognition of NFATp/AP-1 composite elements within genes induced upon the activation of immune cells.
###end article-title 118
###begin article-title 119
A Gata2 intronic enhancer confers its pan-endothelia-specific regulation.
###end article-title 119
###begin article-title 120
###xml 57 62 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The T cell activation factor NF-ATc positively regulates HIV-1 replication and gene expression in T cells.
###end article-title 120
###begin article-title 121
VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development.
###end article-title 121
###begin article-title 122
###xml 58 66 <span type="species:ncbi:9606">patients</span>
Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia.
###end article-title 122
###begin article-title 123
MAPping out arteries and veins.
###end article-title 123
###begin article-title 124
FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription.
###end article-title 124
###begin article-title 125
NFAT proteins: key regulators of T-cell development and function.
###end article-title 125
###begin article-title 126
Partners in transcription: NFAT and AP-1.
###end article-title 126
###begin article-title 127
Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3.
###end article-title 127
###begin article-title 128
PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature.
###end article-title 128
###begin article-title 129
Molecular mechanisms of lymphatic vascular development.
###end article-title 129
###begin article-title 130
Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers.
###end article-title 130
###begin article-title 131
###xml 42 47 <span type="species:ncbi:10090">mouse</span>
Mapping Wnt/beta-catenin signaling during mouse development and in colorectal tumors.
###end article-title 131
###begin article-title 132
TRANSFAC: transcriptional regulation, from patterns to profiles.
###end article-title 132
###begin article-title 133
Mutations in FOXC2 are strongly associated with primary valve failure in veins of the lower limb.
###end article-title 133
###begin article-title 134
###xml 54 63 <span type="species:ncbi:10258">Orf virus</span>
A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases.
###end article-title 134
###begin article-title 135
NFAT1 and NFAT2 are positive regulators of IL-4 gene transcription.
###end article-title 135
###begin article-title 136
IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1.
###end article-title 136
###begin article-title 137
Comparison of sample preparation methods for ChIP-chip assays.
###end article-title 137
###begin article-title 138
A novel type of vascular endothelial growth factor: VEGF-E (NZ-7 VEGF) preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain.
###end article-title 138
###begin article-title 139
Lymphatic vasculature development.
###end article-title 139
###begin article-title 140
Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor.
###end article-title 140
###begin article-title 141
Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis.
###end article-title 141
###begin article-title 142
###xml 38 43 <span type="species:ncbi:9606">human</span>
Cloning and characterization of seven human forkhead proteins: binding site specificity and DNA bending.
###end article-title 142
###begin article-title 143
The transcription factor NF-ATc is essential for cardiac valve formation.
###end article-title 143
###begin article-title 144
Mechanisms of angiogenesis.
###end article-title 144
###begin article-title 145
High-throughput SELEX SAGE method for quantitative modeling of transcription-factor binding sites.
###end article-title 145
###begin article-title 146
Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes.
###end article-title 146
###begin article-title 147
Lymphangiogenic gene therapy with minimal blood vascular side effects.
###end article-title 147
###begin article-title 148
Calcineurin is a potent regulator for skeletal muscle regeneration by association with NFATc1 and GATA-2.
###end article-title 148
###begin article-title 149
Essential structural and functional determinants within the forkhead domain of FOXC1.
###end article-title 149
###begin article-title 150
Vascular development: molecular logic for defining arteries and veins.
###end article-title 150
###begin article-title 151
Calcineurin signaling and NFAT activation in cardiovascular and skeletal muscle development.
###end article-title 151
###begin article-title 152
###xml 119 123 <span type="species:ncbi:10090">mice</span>
Abnormal recruitment of periendothelial cells to lymphatic capillaries in digestive organs of angiopoietin-2-deficient mice.
###end article-title 152
###begin article-title 153
###xml 67 72 <span type="species:ncbi:4932">yeast</span>
Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes.
###end article-title 153
###begin article-title 154
The role of NFAT in osteoclast formation.
###end article-title 154
###begin article-title 155
Therapeutic differentiation and maturation of lymphatic vessels after lymph node dissection and transplantation.
###end article-title 155
###begin article-title 156
Angiopoietin-1 promotes lymphatic sprouting and hyperplasia.
###end article-title 156
###begin article-title 157
Gibbs recursive sampler: finding transcription factor binding sites.
###end article-title 157
###begin article-title 158
Redundant expression but selective utilization of nuclear factor of activated T cells family members.
###end article-title 158
###begin article-title 159
###xml 49 54 <span type="species:ncbi:10090">mouse</span>
The early development of the lymphatic system in mouse embryos.
###end article-title 159
###begin article-title 160
###xml 100 115 <span type="species:ncbi:10090">transgenic mice</span>
Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice.
###end article-title 160
###begin article-title 161
Intrinsic versus microenvironmental regulation of lymphatic endothelial cell phenotype and function.
###end article-title 161
###begin article-title 162
Calcineurin-GATA-6 pathway is involved in smooth muscle-specific transcription.
###end article-title 162
###begin article-title 163
###xml 29 34 <span type="species:ncbi:9606">human</span>
Transcriptomal comparison of human dermal lymphatic endothelial cells ex vivo and in vitro.
###end article-title 163
###begin article-title 164
###xml 54 60 <span type="species:ncbi:10090">murine</span>
Prox1 function is required for the development of the murine lymphatic system.
###end article-title 164
###begin article-title 165
An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype.
###end article-title 165
###begin article-title 166
In Situ Hybridization: A Practical Approach.
###end article-title 166
###begin article-title 167
Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting.
###end article-title 167
###begin article-title 168
MFH-1 is required for bone morphogenetic protein-2-induced osteoblastic differentiation of C2C12 myoblasts.
###end article-title 168
###begin p 169
Abbreviations used in this paper: CEAS, cis-regulatory element annotation system; ChIP, chromatin immunoprecipitation; CsA, cyclosporine A; EMSA, electrophoretic mobility shift assay; FDR, false discovery rate; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; iLEC, intestinal LEC; LEC, lymphatic endothelial cell; MAT, model-based analysis of tiling array; NFAT, nuclear factor of activated T cells; SLC, secondary lymphoid chemokine; SMA, smooth muscle actin; SMC, smooth muscle cell.
###end p 169

